Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.626232
Title: Validation of phosphodiesterase isozymes as targets for pulmonary hypertension
Author: Trinder, S. L.
Awarding Body: University College London (University of London)
Current Institution: University College London (University of London)
Date of Award: 2013
Availability of Full Text:
Access through EThOS:
Full text unavailable from EThOS. Please try the link below.
Access through Institution:
Abstract:
Pulmonary hypertension (PH) is a debilitating disease with a very poor prognosis. Increasing lung cyclic GMP (cGMP) levels is clinically effective in treating the disease, but since many endogenous pathways regulate cGMP synthesis and metabolism, there exists considerable scope for further optimising cGMP-based therapy. In this thesis I have explored this possibility focusing on natriuretic peptides, vasoactive mediators that stimulate cGMP synthesis via a membrane-bound guanylate cyclase, and phosphodiesterases (PDE) which inactivate cGMP. Using organ bath pharmacology, I assessed the functional reactivity of systemic (aorta) and pulmonary vessels in response to atrial natriuretic peptide (ANP) and nitric oxide (NO; in the form of an NO-donor) in the absence and presence of isoform-selective PDE inhibitors. This was conducted in tissues from normoxic rats and animals exposed to 2 weeks hypoxia (10% O2). In addition, I undertook RT-PCR studies to determine if expression of specific PDEs changed in these vessels under a hypoxic environment. My data suggest that PDE 2 and PDE 5 are the principal PDE isoforms regulating ANP-dependent vasorelaxation in the pulmonary vasculature (from a functional and expressional standpoint) and that inhibition of these PDEs should bring about a selective pulmonary dilatation, particularly under hypoxic conditions. Using a model of hypoxia-induced PH, I demonstrated that the PDE2 inhibitor, BAY 60-7550, prevents the pulmonary hypertension, pulmonary vascular remodelling and right ventricular hypertrophy characteristic of the disease. Moreover, combination of BAY 60-7550 with the neutral endopeptidase inhibitor ecadotril (augments circulating natriuretic peptide levels) produces an additive, if not synergistic, benefit against disease severity. Finally, I built on published work from our laboratory by investigating the effect of the PDE5 inhibitor sildenafil, in combination with ecadotril, in experimental models of PH and pulmonary fibrosis. Again, my data suggest that targeting PDE5 is also an effective therapeutic approach in these lung disorders.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.626232  DOI: Not available
Share: